Name: TG101348 (SAR302503)
Price: 292.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    TG101348, also known as SAR302503, is a potent and selective inhibitor of janus kinase 2 (JAK2), one member of a family of 4 cytoplasmic tyrosine kinases including janus kinase 1(JAK1), JAK2, janus kinase 3 (JAK3) and tyrosine kinase 2 (Tyk2), with the inhibition constant IC50 of 3 nM. Comparing to other close related kinases, the selectivity of TG101348 for JAK2 is 35- and 334-fold stronger than that for JAK3 and JAK1 respectively. TG10348 is capable of inducing apoptosis in HEL cells as well BaF/3 cells harboring JAK2V617 mutation and inhibiting hematopoietic progenitor colony formation and erythroid engraftment in samples from polycythemia vera (PV) patients.
- Properties
  - Alternative Name
    
    Tg-101348,SAR-302503; N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
    
    CAS Number
    
    936091-26-8
    
    Molecular Formula
    
    C27H36N6O3S
    
    Molecular Weight
    
    524.68
    
    Appearance
    
    A solid
    
    Purity
    
    99.51%
    
    Solubility
    
    ≥26.23 mg/mL in DMSO; insoluble in H2O; ≥6.69 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Deng R, Zhang P, et al. "HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer." Clin Epigenetics. 2018 Dec 11;10(1):153. PMID:30537988
    2. Quan Y, Xu H, et al. "JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1." J Virol. 2017 Apr 13;91(9). pii: e00075-17. PMID:28202754

TG101348 (SAR302503)

TG101348 (SAR302503)

Background

We Also Recommend

AG-490

AZD1480

Tofacitinib (CP-690550,Tasocitinib)